PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 350K 700K 1.1M Q4 '12: 0 Q1 '13: 0 Q2 '13: 0 Q4 '15: 0 Q1 '16: 0 Q2 '16: 0 Q3 '16: 0 Q4 '22: 989K Q1 '23: 1M Q2 '23: 846.6K Q3 '23: 601.4K Q4 '23: 557.7K Q1 '24: 590.8K Q2 '24: 683.9K Q3 '24: 723.9K Q4 '24: 617.1K Q1 '25: 657.7K Q2 '25: 460.2K Q3 '25: 350.4K Q4 '25: 336.1K Q1 '13 Q1 '16 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-30M -20M -10M 0 10M 20M 30M Q4 '10: -20.7M Q1 '11: -22M Q2 '11: -21.9M Q3 '11: -21.9M Q4 '11: -21.4M Q1 '12: -21.5M Q2 '12: -20.4M Q3 '12: -16.5M Q4 '12: -14.3M Q1 '13: -13.4M Q2 '13: -12.4M Q3 '13: -12.4M Q4 '13: -13M Q1 '14: -14.2M Q2 '14: -15M Q3 '14: -15.2M Q4 '14: -12.6M Q1 '15: -12.9M Q2 '15: -13.3M Q3 '15: -15.3M Q4 '15: -24.7M Q1 '16: -28.5M Q2 '16: -29M Q3 '16: -29M Q4 '16: -24.5M Q1 '17: -20.4M Q2 '17: -18.7M Q3 '17: -15.9M Q4 '17: -13.4M Q1 '18: -11.7M Q2 '18: -10.5M Q3 '18: -8.9M Q4 '18: -8.1M Q1 '19: -7.2M Q2 '19: -6.9M Q3 '19: -7M Q4 '19: -6.3M Q1 '20: -6M Q2 '20: -5.3M Q3 '20: -5M Q4 '20: -5M Q1 '21: -4.7M Q2 '21: -4.7M Q3 '21: -4.7M Q4 '21: -4.7M Q1 '22: -4.5M Q2 '22: -4.3M Q3 '22: -4M Q4 '22: -3.4M Q1 '23: -3.2M Q2 '23: -2.9M Q3 '23: -3M Q4 '23: -2.9M Q1 '24: -2.6M Q2 '24: -2.6M Q3 '24: -2.8M Q4 '24: -4.5M Q1 '25: -5.2M Q2 '25: -6.2M Q3 '25: -6.5M Q4 '25: -5.3M Q1 '26: -5.4M Q2 '26: -4.6M Q2 '12 Q2 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

Net Income TTM

-45M -30M -15M 0 15M 30M 45M Q4 '10: -18.6M Q1 '11: -20.1M Q2 '11: -21.2M Q3 '11: -20.7M Q4 '11: -19.4M Q1 '12: -18.9M Q2 '12: -18.2M Q3 '12: -14.1M Q4 '12: -12.6M Q1 '13: -12.3M Q2 '13: -10.8M Q3 '13: -13M Q4 '13: -27.7M Q1 '14: -30.2M Q2 '14: -28.5M Q3 '14: -27.7M Q4 '14: -10.2M Q1 '15: -8.1M Q2 '15: -12M Q3 '15: -14M Q4 '15: -24.5M Q1 '16: -28.5M Q2 '16: -29M Q3 '16: -29.1M Q4 '16: -24.4M Q1 '17: -20.3M Q2 '17: -18.6M Q3 '17: -15.8M Q4 '17: -13.5M Q1 '18: -12M Q2 '18: -10.2M Q3 '18: -8.7M Q4 '18: -8.2M Q1 '19: -6.6M Q2 '19: -7.3M Q3 '19: -7.6M Q4 '19: -6.9M Q1 '20: -7.4M Q2 '20: -6.8M Q3 '20: -6.6M Q4 '20: -6.7M Q1 '21: -6.5M Q2 '21: -6.5M Q3 '21: -6M Q4 '21: -5.5M Q1 '22: -4.9M Q2 '22: -4.4M Q3 '22: -4.1M Q4 '22: -3.6M Q1 '23: -3.4M Q2 '23: -3.1M Q3 '23: -3.2M Q4 '23: -3.1M Q1 '24: -2.8M Q2 '24: -2.8M Q3 '24: -3M Q4 '24: -4.7M Q1 '25: -5.4M Q2 '25: -6.3M Q3 '25: -6.6M Q4 '25: -5.4M Q1 '26: -5.6M Q2 '26: -4.7M Q2 '12 Q2 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-24M -16M -8M 0 8M 16M 24M Q2 '11: -16.7M Q3 '11: -17.2M Q4 '11: -17.2M Q1 '12: -15.7M Q2 '12: -13.4M Q3 '12: -11.9M Q4 '12: -11.3M Q1 '13: -11.4M Q2 '13: -10.5M Q3 '13: -11M Q4 '13: -9.9M Q1 '14: -9.8M Q2 '14: -11.2M Q3 '14: -11.9M Q4 '14: -13.8M Q1 '15: -15.2M Q2 '15: -15.8M Q3 '15: -16.6M Q4 '15: -17.4M Q1 '16: -21.3M Q2 '16: -22.1M Q3 '16: -22.9M Q4 '16: -21.9M Q1 '17: -17.1M Q2 '17: -14.6M Q3 '17: -11.9M Q4 '17: -10.3M Q1 '18: -8.9M Q2 '18: -8.2M Q3 '18: -6.9M Q4 '18: -5.2M Q1 '19: -5.5M Q2 '19: -5.3M Q3 '19: -5.9M Q4 '19: -6.2M Q1 '20: -4.8M Q2 '20: -4.3M Q3 '20: -4.3M Q4 '20: -4.1M Q1 '21: -4.5M Q2 '21: -4.2M Q3 '21: -3.6M Q4 '21: -1M Q1 '22: -492K Q2 '22: -663.8K Q3 '22: -664.7K Q4 '22: -3M Q1 '23: -3.1M Q2 '23: -2.8M Q3 '23: -2.8M Q4 '23: -2.6M Q1 '24: -3M Q2 '24: -3.1M Q3 '24: -2.9M Q4 '24: -3.3M Q1 '25: -3.3M Q2 '25: -3.1M Q3 '25: -3.4M Q4 '25: -3.3M Q1 '26: -2.6M Q2 '26: -2.4M Q2 '12 Q2 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

Free Cash Flow TTM

-15M -10M -5M 0 5M 10M 15M Q2 '12: -13.4M Q3 '12: -11.9M Q4 '12: -11.3M Q1 '13: -11.4M Q2 '13: -10.5M Q3 '13: -11M Q4 '13: -9.9M Q1 '14: -9.8M Q2 '14: -11.2M Q3 '14: -11.9M Q4 '14: -13.9M Q2 '12 Q4 '12 Q2 '13 Q4 '13 Q2 '14 Q4 '14

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 150M 300M 450M Q1 '21: 402.2M Q2 '21: 403.6M Q3 '21: 410M Q1 '22: 419.4M Q2 '22: 419.4M Q3 '22: 419.5M Q1 '23: 419.5M Q2 '23: 419.5M Q3 '23: 419.5M Q1 '24: 419.5M Q2 '24: 419.5M Q3 '24: 419.9M Q1 '25: 420.3M Q2 '25: 420.3M Q3 '25: 420.3M Q1 '26: 420.3M Q2 '26: 420.3M Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-0.24 -0.16 -0.08 0.00 0.08 0.16 0.24 Q4 '13: -0.21 Q1 '14: -0.21 Q2 '14: -0.19 Q3 '14: -0.18 Q4 '14: -0.06 Q1 '15: -0.04 Q2 '15: -0.06 Q3 '15: -0.07 Q4 '15: -0.12 Q1 '16: -0.14 Q2 '16: -0.14 Q3 '16: -0.15 Q4 '16: -0.12 Q1 '17: -0.09 Q2 '17: -0.08 Q3 '17: -0.05 Q4 '17: -0.04 Q1 '18: -0.04 Q2 '18: -0.03 Q3 '18: -0.02 Q4 '18: -0.01 Q1 '19: 0.00 Q2 '19: -0.01 Q3 '19: -0.01 Q4 '19: -0.02 Q1 '20: -0.02 Q2 '20: -0.01 Q3 '20: -0.01 Q4 '20: -0.01 Q1 '21: -0.01 Q2 '21: -0.01 Q3 '21: -0.01 Q4 '21: 0.00 Q1 '22: 0.00 Q2 '22: 0.00 Q3 '22: 0.00 Q4 '22: 0.00 Q1 '23: 0.00 Q2 '23: 0.00 Q3 '23: 0.00 Q4 '23: 0.00 Q1 '24: 0.00 Q2 '24: 0.00 Q3 '24: 0.00 Q4 '24: 0.00 Q1 '25: 0.00 Q2 '25: 0.00 Q3 '25: 0.00 Q4 '25: 0.00 Q1 '26: 0.00 Q2 '26: 0.00 Q1 '14 Q4 '15 Q3 '17 Q2 '19 Q1 '21 Q4 '22 Q3 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.